

Update in Anaesthesia

Ebola – critical care considerations

Lisa Molus and Paul Bush

Correspondence: bruce.mccormick@nhs.net

Originally published as *Anaesthesia Tutorial of the Week 315*, 16 April 2015. Edited by Niraj Niranjan and Harry Singh

Summary

Although the threat of imported cases to the UK and other international countries is low, there remains the distinct possibility that further cases may occur.

Consider Ebola virus disease (EVD) as a differential diagnosis in anyone with a positive exposure history and recent fever $\geq 37.5^{\circ}\text{C}$.

If deemed at risk, immediate isolation in a ward-level bed and discussion with local infectious disease service is paramount.

Diagnostic tests may take up to 8 h to receive a result.

EVD has a high mortality but survival outcomes improve with aggressive supportive care with intravenous fluid and electrolyte replacement.

Local escalation policies should be pre-agreed and followed.

All confirmed EVD cases should be transferred to a specialist High Level Isolation Facility for further management.

INTRODUCTION

Ebola virus disease (EVD), previously known as Ebola haemorrhagic fever, is a rare, life-threatening viral illness caused by infection with one of the Ebola virus strains. The most recent epidemic of EVD, beginning in March 2014, has been the largest recorded outbreak, in terms of both geographical spread and case numbers. It has affected multiple countries in West Africa, amongst which the most affected are Guinea, Liberia and Sierra Leone. In late July the World Health Organization (WHO) declared the outbreak a 'Grade 3 emergency response' and, later, in early August, a 'Public health emergency of international concern'.

Cases have been reported in Nigeria, Senegal, Mali, the USA, Spain and the UK. The management of EVD raises a number of practical, logistic and ethical issues. This article aims to discuss the management of suspected and confirmed cases of EVD from a critical care perspective. It is based on recent publications from WHO, the Centers for Disease Control and Prevention (CDC), Public Health England (PHE) and the North of England Critical Care Network (NoECCN).

Lisa Molus

CT2 Anaesthetics
Sunderland Royal Infirmary
UK

Paul Bush

Consultant in Anaesthetics
and Intensive Care
University Hospital North
Durham
UK

HISTORY

EVD is caused by the genus *Ebolavirus*, which is part of the Filovirus family. Filoviruses can cause severe haemorrhagic fever in human and non-human primates. Four of the five known species of *Ebolavirus* can cause disease in humans: Zaire, Sudan, Tai Forest and Bundibugyo. The fifth species, Reston, has caused severe illness only in non-human primates.¹

Ebola was first discovered in 1976 in almost simultaneous outbreaks occurring in the Democratic Republic of Congo near the Ebola River, from which the disease takes its name, and in South Sudan. The disease then disappeared after 1979 and did not reappear again until 1994 in Gabon. Since 1994 sporadic outbreaks have been occurring with increasing frequency.²

CURRENT EPIDEMIOLOGY

The current (2014) epidemic is caused by the Zaire species. It is by far the most widespread and intense outbreak recorded and, as of 6 February 2015, a total of 22,495 clinically compatible cases of EVD,




Figure 1. Cumulative clinically compatible cases in Guinea, Liberia and Sierra Leone as of 4 February 2015³

including 8981 deaths, have been reported globally (Figure 1). This number is believed to be an under-representation, as many cases will be cared for outside the hospital setting.

At present, there have been six non-medically repatriated cases of EVD diagnosed outside Africa: three imported cases (one in the UK and two in the USA) and three incidents of local transmission to health care workers (one in Spain and a further two in the USA). With regard to medically repatriated cases, a total of 18 patients with confirmed have been evacuated from Africa. Of these, 14 have been discharged from hospital and four have died.

The Zaire species of *Ebolavirus* is one of the most virulent human pathogens known. The overall case fatality rates in the three intense transmission countries (Guinea, Liberia and Sierra Leone) are estimated to be as high as 71% whilst, among those hospitalised, mortality rates are slightly lower, at 60%. The mortality rate is seen to fall further in EVD cases being treated outside of Africa, at approximately 20%.

The risk of further EVD cases being imported to Europe and the USA is still considered to be very low because robust monitoring and surveillance measures are in place. However, there remains a distinct possibility that additional cases may occur in the upcoming months, giving rise to concerns for the impact this may have on national health services.³

PATHOGENESIS

The natural reservoir of Ebola virus has not yet been identified. The first human case in an outbreak occurs through contact with the

body fluids of an infected animal. Person-to-person transmission then follows through:

- direct contact with blood or body fluids (including but not limited to urine, saliva, faeces, vomit, breast milk, semen and sweat) of an infected individual
- contact with objects contaminated with infected fluids in the absence of strict infection control measures.

Traditional burial practices in West Africa, where mourners have direct contact with the bodies of the deceased, have significantly driven the transmission of EVD. Transmission via sexual contact with a convalescent case is also possible as the virus is present in semen and vaginal fluids for up to 3 months after recovery.²

Infection begins once the virus gains entry through unprotected mucous membranes, breaks in skin integrity or via the parenteral route. There is no evidence of transmission of EVD through intact skin or through small droplet spread, such as coughing or sneezing. The virus migrates to regional lymph nodes and subsequently disseminates to the liver, spleen and adrenal glands, affecting a number of target cells, including monocytes, macrophages, dendritic cells, endothelial cells, fibroblasts, hepatocytes, adrenal cortical cells and epithelial cells.

Although not infected by Ebola virus, lymphocytes undergo apoptosis, resulting in decreased lymphocyte counts and an altered immune response by modulation of gene expression. An early antibody response and high lymphocytic count during the infection are associated with survival. Hepatocellular and adrenocortical necrosis occur, causing coagulopathy and shock from impaired steroid synthesis respectively.

Ebola virus appears to induce cytokine and other proinflammatory mediator release with subsequent loss of vascular integrity and coagulation defects ultimately resulting in multiorgan failure and shock.⁴ The pathogenesis of shock is multifactorial and includes fluid loss, fluid sequestration, coagulopathy and sepsis due to secondary infections.

CLINICAL PRESENTATION

Patients with EVD will develop symptoms within 21 days of infection and any symptoms following this period will not be due to Ebola virus. The onset of symptoms typically occurs after an incubation period of approximately 9–11 days. Table 1 outlines the symptoms of EVD. Such non-specific symptoms can be easily mistaken for those of other infectious diseases such as malaria or typhoid fever, or with any other viral or bacterial infection, so a comprehensive travel and exposure history must be obtained.

Patients with fatal disease typically develop more severe clinical signs early during infection and usually succumb to the disease between days 6 and 16. In less severe cases, patients have fever for several days and improve around day 6. Risk factors associated with a poor outcome in the affected West African countries are shown in Table 2.⁵

INFECTION CONTROL

Prior to isolation, if the patient has been in a public area, the hospital lead for infection control and the local health protection team must be notified, and the area cornered off and decontaminated. All staff

Table 1. Early and late signs and symptoms of Ebola virus disease⁵

Early	Late
Fever	Severe watery diarrhoea
Rash (maculopapular)	Vomiting
Sore throat	Abdominal pain
Myalgia and arthralgia	Petechiae
Malaise	Hypovolaemic shock
Severe headache	Haemorrhagic manifestations, e.g. mucosal or gastrointestinal

Table 2. Risk factors associated with a poor outcome in West African countries⁵

Age > 45 years
Unexplained haemorrhage
Associated symptoms such as:
• chest pain
• shortness of breath
• headache
• confusion and convulsions

and members of the public who may have come into physical contact with the patient or body fluids should be assessed.

Infection control measures are a critical part of clinical management. Person-to-person transmission of Ebola virus requires direct contact with body fluids (e.g. blood, faeces or vomit) from a person who has developed symptoms. Therefore, in a secondary care setting, the rapid identification and subsequent isolation of high-risk patients is paramount. The patient should be isolated in a single room with an adjacent contained space to be used for the removal of personal protective equipment (PPE) and waste disposal.

Only staff trained in the correct use of PPE should have patient contact. Staff should attend the patient in pairs with a third member in the relevant PPE outside the room to assist as required. A fourth member of staff should act as a safety officer, ensuring correct PPE use and adherence to local protocols for the safe donning and doffing of PPE.⁶

The use of PPE is mandatory, and guidance from the CDC sets out protection standards for dealing with suspected cases of EVD. Recommended PPE includes the following:

- hand hygiene with soap and water or an alcohol based hand rub
- single-use double gloves with extra-long cuffs
- fluid-resistant single-use coveralls extending to the mid-calf
- fluid-resistant single-use aprons if patients have vomiting or diarrhoea
- respiratory protective equipment (RPE) to reduce the risk of aerosol spread such as:
 - powered air-purifying respirator (PAPR) with a full face shield, helmet or headpiece
 - N95 or higher respirator in combination with disposable surgical hood extending to shoulders and single-use full face shield.⁷

Note that the above are recommendations and that individual facilities may elect to use PPE that varies from that outlined depending on local resources.

The key to effective and safe use of any PPE is through consistent implementation by repeated training and practice. Facilities should standardise the PPE in use and provide clear written protocols to avoid the risk of contamination.⁷

CLEANING AND WASTE MANAGEMENT

Contaminated equipment or surfaces should be cleaned and disinfected in a timely manner using standard hospital disinfectants (e.g. 0.5% chlorine solution). Contaminated material must be immediately segregated at the point of generation, sealed in appropriately labelled containers and destroyed within 24 hours. The preferred method of waste disposal is autoclaving with the contents appropriately disposed of in a designated pit.

Handling of human remains should be kept to a minimum. Appropriately trained personnel must use full PPE when handling the remains of a suspected or confirmed case of EVD. The body should be placed in a leak-proof double bag, with the surface of each body bag being decontaminated with a suitable disinfectant. The body should immediately be transported to the mortuary or the cemetery and buried promptly. Spraying, washing or embalming of remains in preparation for burial should be discouraged.

Owing to the highly infectious nature of the remains, post-mortem examinations should be limited to essential evaluations only and, again, must be carried out by trained personnel wearing full PPE.⁸

DIAGNOSIS

The diagnosis of EVD should follow a step-wise approach comprising a comprehensive history, physical examination and relevant investigations. A high index of suspicion of EVD should be present when faced with any individual manifesting the signs and symptoms detailed above along with a positive exposure history.

Current practice in the UK is based upon recent guidelines published by the College of Emergency Medicine. Patients are suspected to be at high risk of EVD if:

1. they have travelled from one of the affected areas (currently Guinea, Liberia and Sierra Leone) *or* have had contact with an individual with EVD within the previous 21 days, *and*
2. they have a fever ($\geq 37.5^{\circ}\text{C}$) or history of fever in the past 24 hours.⁶

However, as the symptoms of EVD are non-specific and may mimic those of other diseases, a definitive diagnosis can be made only by using specific laboratory diagnostic tests including enzyme-linked immunosorbent assay (ELISA) testing, polymerase chain reaction (PCR) and virus isolation.

Ebola virus can be detected in serum samples only after the onset of symptoms, when the viral load is increasing. Diagnostic tests are usually performed on samples of serum and EDTA-treated blood and/or urine. In the UK, samples are sent to the Rare and Imported Pathogens Laboratory (RIPL) in Wiltshire, England. In addition to EVD, all samples are tested for other potential causes of fever that the patient may have been exposed to, including, but not limited, to Marburg virus disease, Dengue fever and malaria.

For urgent samples, results may be available within 7–8 hours of sample receipt. Positive results are immediately telephoned to the referring clinician to aid in the timely patient management, infection control and public health response.⁹ It may take up to 3 days after the onset of symptoms for the virus to reach detectable levels. It is therefore essential, following an initial negative sample, to send a second sample for testing after at least 48 hours owing to the possibility of a false-negative result.¹⁰

Other supplementary laboratory investigations include haematological and biochemical tests. Findings may demonstrate low white blood cell counts followed later by elevated neutrophils. Serum amylase and hepatic transaminases may be raised, reflecting pancreatic and hepatic involvement. Blood coagulation tests may demonstrate a picture consistent with DIC such as prolonged prothrombin time (PT) and partial thromboplastin times (PTT), elevated fibrin degradation products and thrombocytopenia.⁵

MANAGEMENT

The increasing international response to the current outbreak has meant that a large number of international health care and military staff have been deployed to aid countries where transmission is widespread. Such workers have been identified as being at obvious risk of EVD, and the CDC and other national agencies have issued guidance for the monitoring, surveillance and, if indicated, escalation plans for returning staff based on their exposure risk.¹¹

Individuals with suspected EVD are likely to initially present to a peripheral hospital so acute health services should have local management protocols in place. Discussion with infectious disease clinicians will help determine whether transfer to a high-level infection unit (HLIU) is indicated.

In peripheral hospitals, it is recommended that cases be managed with the best available PPE, in a ward-level isolation room rather than a critical care setting. The decision to escalate or de-escalate care should be made on a case-by-case basis, taking into consideration the potential risks to the patient and staff. This decision-making process raises many ethical and practical issues so must be based on agreement between at least two local consultants (such as emergency department and critical care consultants) and advice from an infectious disease consultant.

In confirmed cases, a number of key teams are alerted including the outbreak control team, public health and senior government officials, and the clinical team at the nearest HLIU.¹² Currently there is no licensed treatment or vaccine for EVD and the mainstay of treatment is primarily supportive. Care focuses on the early detection and supportive care of complications such as hypoxia, hypovolaemia, electrolyte and coagulation abnormalities, septic shock, multiorgan failure and disseminated intravascular coagulation (DIC). This standard supportive care should be provided by the hospital concerned within the limitations of the strict infection control measures.

Monitoring

The monitoring of patients' vital signs, fluid balance and neurological status through non-invasive means (e.g. pulse oximetry, heart monitor, non-invasive blood pressure) should be carried out on a frequent basis guided by the patient's clinical condition. Accurate documentation of fluid balance may be difficult particularly in the setting of vomiting and diarrhoea; therefore, hourly monitoring of urine output via a Foley catheter and urometer is essential.

If available, invasive arterial blood pressure monitoring should be considered in those with haemodynamic instability requiring vasopressor support or when frequent blood samples are being taken. Insertion of a central venous line (CVL) solely for central venous pressure (CVP) monitoring is not recommended and in general the use of any form of invasive monitoring should be limited to reduce the risk of exposure to health care staff.

Airway management and ventilation

Respiratory involvement is not a common feature of EVD, although in severe cases respiratory failure may occur. Airway management may otherwise be required to protect the airway from aspiration in those with reduced level of consciousness or upper gastrointestinal haemorrhage.

The CDC strongly recommend that aerosol-generating procedures such non-invasive ventilation, bronchoscopy, sputum induction, intubation and extubation and open suctioning of airways be avoided if at all possible. In addition, ventilatory support has yet to demonstrate a significant improvement in survival rates and therefore may not be offered depending on local protocol.

If ventilatory support is to be offered, the Canadian Critical Care Society recommends early intubation with traditional mechanical ventilation in a negative pressure isolation room by highly experienced clinicians wearing appropriate PPE.¹³

Cardiovascular support and intravenous access

Careful attention to intravascular volume status and aggressive administration of fluids and electrolytes (with a special focus on potassium, calcium and bicarbonate supplementation) constitutes the first step in a series of supportive care interventions. In the non-critically ill patient this should be achieved via the oral route.

Intravenous access is required in those unable to tolerate the oral route or in the presence of haemodynamic instability. Hartmann's or Ringer's lactate has been suggested as the fluid of choice for volume replacement. Large-bore peripheral intravenous (IV) access

is suitable for those with milder disease with central venous access required for those needing IV electrolyte replacement or with poor peripheral access. In the event of the need to establish central venous access, the risk of injury and exposure can be minimised by having an experienced clinician conduct the procedure under ultrasound guidance. Needle-less systems may be used to avoid sharps injuries and the use of non-suture securing devices is advocated.

Cardiovascular support with vasopressors may be indicated, these may be administered via either the peripheral or central route depending on local protocol. Vigilance must be taken with fluid replacement as with the systemic inflammatory response and loss of vascular integrity, profound third space losses have been observed. The correction of haematological and coagulation abnormalities with blood products may also be necessary.¹³

Renal support

Renal failure is common in severe cases. Dialysis for renal failure is considered a high-risk intervention for health care staff and the Royal Free Hospital in London has therefore ruled out offering this. In the USA, however, the CDC recommend that the care of patients with EVD should be undertaken in a hospital with the capacity to perform continuous renal replacement therapy (CRRT). This highlights the importance of regional and national guidelines in outlining clear escalation and management policies.¹⁴

Symptom management

Symptoms control is a significant component of EVD management (Table 3).

Antibiotics and experimental therapies

The treatment of secondary bacterial infections and use of broad-spectrum antibiotics has been suggested in patients with evidence of septic shock and secondary infection. The early discontinuation of antibiotic therapy should be considered if microbiology results and other investigations do not reveal bacterial superinfection. Other management options may include the early utilisation of

Table 3. Symptoms of EVD and the appropriate management¹²

Symptom	Management
Pain	Opiates titrated to effect e.g. fentanyl, morphine
Fever	Paracetamol (max. 4 g per 24 hours), lower dose in hepatic dysfunction Non-steroidal anti-inflammatory drugs should be avoided because of their platelet inhibition and renal effects
Dyspnoea	Supplemental oxygen
Seizure	Airway management. Benzodiazepines. Laboratory investigations (Na ⁺ , glucose). CT of the head if focal signs are present
Nausea and vomiting	Antiemetics. Consider nasogastric tube and suction
Poor oral intake	Where available, delayed total parenteral nutrition if enteral not tolerated
Agitation	Haloperidol

experimental monoclonal antibody therapy such as ZMapp (Mapp Biopharmaceuticals Inc, San Diego, CA, USA). The clinical benefit of ZMapp remains unproven and further trials are required to assess efficacy. Beyond Zmapp, the development and testing of other antiviral therapies and experimental vaccines is also picking up pace.^{5,15}

Patients who make a successful recovery from EVD develop antibodies that last for at least 10 years. It is not known if people who recover are immune for life or if they can become infected with a different strain of *Ebolavirus*.⁵

PAEDIATRIC CONSIDERATIONS

There are additional issues that must be considered when managing suspected or confirmed EVD in the paediatric population. There is limited information on the current outbreak and the impacts this has on children. However, because their circulating blood volumes are smaller, children are more likely to become fluid depleted as a result of vomiting or diarrhoea, so without rapid intervention, they have the potential to deteriorate more rapidly than adults. Thus, it may be desirable to transfer children to a specialist HLIF at an earlier stage (i.e. prior to laboratory diagnosis of EVD) than would be the case for an adult.

Children depend on their parents or caregivers for their physical needs and psychological support so the isolation and quarantine of children poses a challenge. With most infectious diseases, children are often isolated with a parent. However, in the case of EVD, because of the risk of parental exposure, parents may need to be separated from their child. This may impact on the child's compliance with treatment especially when confronted with clinical staff in full PPE.

The decision to allow parents to accompany a child or to administer sedation to aid with management must be made on a case-by-case basis. Hospital protocols, public health advice and the level of exposure between parent and child that may have occurred before seeking medical care must all be taken into consideration.¹⁶

ETHICAL ISSUES OF ESCALATION

The prioritisation and allocation of finite critical care resources occurs routinely throughout the health service. The provision of critical care is based on clinical decisions allowing for the most effective and ethically sound allocation of resources, free from external, political and public influences.

In EVD the most likely situation is that small numbers of patients will require simultaneous treatment. However, the treatment of a single EVD patient will require extraordinary resources. If exceptional demand is placed on critical care, such that resources cannot be provided to all patients who have the ability to benefit, the threshold for accessing critical care consequently rises.

Despite EVD's current prominence in the media and in public interest, the clinical and ethical principles underpinning such decision-making processes remain unchanged. This must be done on an individual case-by-case basis, with the patient with the higher clinical likelihood of benefit being given precedence.

In the case of EVD, there are two main conflicting ethical stances regarding the allocation of scarce critical care resources. The first approach attempts to weigh the potential benefits against harm and, in doing so, a balanced judgement can be made which results in the greatest net benefit. Taking into consideration the high mortality rate, the high risk of secondary contamination to health care staff and the subsequent denial of effective treatments for other patients due to redistribution of resources, the refusal of level 3 care for patients with confirmed EVD can be justified as the overall perceived harm outweighs the limited expected gains.

The opposing view considers our duties and obligations and how best they may be met. Here the argument is that, with strict adherence to infection control measures, the risk to staff and other patients is acceptably low, the reduction in mortality rates with relatively simple supportive care considerable, and the redistribution of work and resources possible with good organisation, planning and communication. This approach would support the provision of critical care interventions to patients with EVD.¹²

PRACTICAL ISSUES OF ESCALATION

Currently, there is limited evidence to support the provision of critical care in the management of EVD as, unlike optimum supportive care, the addition of renal and ventilatory support has yet to demonstrate a significant improvement in survival rates.

This attitude may be set to change, however, as clinical experience is continually increasing as a result of the treatment of EVD patients in the USA and Europe. In practice, the escalation of EVD patients to a critical care setting in a peripheral hospital presents many challenges.

In Texas, for example, a 25-bed critical care unit was closed for several weeks while an imported patient with EVD was treated. The closure of a critical care unit would have a significant impact on the ability of other patients to access a higher level of care. This may result in the restriction of surgeries, conversion of theatre recovery areas and of level 1 and 2 beds to level 3 and the rapid retraining and redeployment of medical and nursing staff. Devoting such resources to patients with EVD is likely to affect the hospital's ability to staff other services.

It is therefore recommended that no peripheral hospital should be required to provide level 3 care to a patient with confirmed EVD. Such patients should ideally be managed in an isolated ward-level bed prior to transfer to a specialist HLIF.¹³

At present, in the UK there is only one HLIF at the Royal Free Hospital in London, comprising two specialist beds available for the management of patients with highly infectious diseases. Three additional infectious disease units in the cities of Newcastle, Sheffield and Liverpool provide surge capacity where EVD patients could be transferred in the event of a larger outbreak, making a total of 26 beds available in the UK.

REFERENCES

- Centers for Disease Control and Prevention (2013). *Viral Hemorrhagic Fevers (VHFs): Filoviridae*. Available: <http://www.cdc.gov/vhf/virus-families/filoviridae.html> (last accessed 14 December 2014).
- Public Health England (2014). *Ebola: overview, History, Origins and Transmission*. Available at: <https://www.gov.uk/government/publications/ebola-origins-reservoirs-transmission-and-guidelines> (last accessed 14 December 2014).
- Public Health England (2015). *Ebola virus disease: epidemiological update: 6 February 2015*. Available: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/402217/EVD_Epidemiological_Update_6_February.pdf (last accessed 13 February 2015).
- Sullivan, N, Yang, Z, Nabel, G. Ebola virus pathogenesis: implications for vaccines and therapies. *J Virology* 2003; **77**: 9733–7.
- Centers for Disease Control and Prevention (2015). *Ebola Virus Disease Information for Clinicians in U.S. Healthcare Settings*. Available: <http://www.cdc.gov/vhf/ebola/hcp/clinician-information-us-healthcare-settings.html> (last accessed 14 January 2015).
- The College of Emergency Medicine, Public Health England. *Ebola Guidance for Emergency Departments*. CEM, London, 2014.
- Centers for Disease Control and Prevention (2014). *Guidance on Personal Protective Equipment To Be Used by Healthcare Workers During Management of Patients with Ebola Virus Disease in U.S. Hospitals, Including Procedures for Putting On (Donning) and Removing (Doffing)*. Available: <http://www.cdc.gov/vhf/ebola/healthcareus/ppe/guidance.html>. (accessed 10 February 2015).
- World Health Organisation (2014). *Interim Infection Prevention and Control Guidance for Care of Patients with Suspected or Confirmed Filovirus Haemorrhagic Fever in Health-Care Settings, with Focus on Ebola*. Available at: http://apps.who.int/iris/bitstream/10665/130596/1/WHO_HIS_SDS_2014.4_eng.pdf?ua=1&ua=1&ua=1 (accessed 26 February 2015).
- Public Health England (2014). *PHE Microbiology Services VHF Sample Testing Queries*. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/388011/PHE_Microbiology_Services_VHF_Sample_Testing_Queries.pdf (last accessed 12 January 2015).
- World Health Organization (2014). *Laboratory diagnosis of Ebola virus disease*. Available at: http://apps.who.int/iris/bitstream/10665/134009/1/WHO_EVD_GUIDANCE_LAB_14.1_eng.pdf (last accessed 26 February 2015).
- Centers for Disease Control and Prevention (2014). *Interim U.S. Guidance for Monitoring and Movement of Persons with Potential Ebola Virus Exposure*. Available at: <http://www.cdc.gov/vhf/ebola/exposure/monitoring-and-movement-of-persons-with-exposure.html> (accessed 11 February 2015).
- North of England Critical Care Network, NHS England. *Guidelines for Escalation of Ebola Virus Disease*. NoECCN, 2014.
- Canadian Critical Care Society (2014). *Ebola Clinical Care Guidelines*. Available from: <http://www.ammi.ca/media/69846/Ebola%20Clinical%20Care%20Guidelines%202%20Sep%202014.pdf> (accessed 26 February 2015).
- Centres for Disease Control and Prevention (2015). *Recommendations for Safely Performing Acute Hemodialysis in Patients with Ebola Virus Disease (EVD) in U.S. Hospitals*. Available at: <http://www.cdc.gov/vhf/ebola/healthcare-us/hospitals/acute-haemodialysis.html> (accessed 13 February 2015).
- Lyon GM, Mehta AK, Varkey JB, et al. Clinical care of two patients with Ebola virus disease in the United States. *NEJM* 2014; **371**: 2402–9.
- American Academy of Pediatrics (2014). *Ebola FAQs*. Available: http://www.aap.org/en-us/advocacy-and-policy/aaphealth-initiatives/Children-and-Disasters/Pages/ebola_faqs.aspx (accessed 11 February 2015).